Breast cancer is the most common cancer in women worldwide.1,2 Nearly 80% of early breast cancers (EBCs) in postmenopausal women are hormone receptor (HR)–positive3; 5-year adjuvant treatment with aromatase inhibitors (AIs) is the gold standard therapy4 for such patients. This evidence concerns the gene CYP19A1 and breast carcinoma.